ENDRA Life Sciences (NDRA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ENDRA Life Sciences Inc. (NASDAQ:NDRA ) Q2 2024 Earnings Conference Call August 22, 2024 4:30 PM ET Company Participants Yvonne Briggs - LHA Investor Relations Alexander Tokman - Acting CEO Ziad Rouag - Head of Regulatory and Clinical Affairs Michael Thornton - Chief Technology Officer Richard Jacroux - CFO Conference Call Participants Edward Woo - Ascendiant Capital Operator Good afternoon, and welcome to the ENDRA Life Sciences Second Quarter 2024 Financial Results Conference Call. All participants will be in listen-only mode.
ENDRA Life Sciences (NASDAQ: NDRA ) stock is up on Monday after the clinical diagnostic ultrasound technology company revealed an investment from S.H.N. Financial Investments Ltd.
| Professional Services Industry | Industrials Sector | Alexander Y. Tokman CEO | NASDAQ (CM) Exchange | 29273B104 CUSIP |
| US Country | 21 Employees | - Last Dividend | 7 Nov 2024 Last Split | 9 May 2017 IPO Date |
ENDRA Life Sciences Inc. is a pioneering company focused on enhancing the capabilities of clinical diagnostic ultrasound through advanced technology. Based in Ann Arbor, Michigan, and incorporated in 2007, ENDRA Life Sciences strives to revolutionize the way diseases are diagnosed and treated, with a special focus on nonalcoholic fatty liver disease. The company has made significant strides in the field through its collaboration with General Electric Company, showcasing its commitment to integrating cutting-edge research and development into practical medical applications.
ENDRA Life Sciences Inc. offers a range of innovative diagnostic imaging technologies aimed at improving patient care through more accurate and non-invasive diagnostics. These technologies include: